Table 1. Baseline characteristics of the study population and HAART study groups.
| Baseline characteristic | Study population n = 770 |
NRTI (n = 96) |
NRTI+IP (n = 180) |
NRTI+ NNRTI (n = 335) |
p-value |
|---|---|---|---|---|---|
| Age (years), median (range) | 40 (26–59) | 40 (28–59) | 40 (28–54) | 40 (26–54) | 0.86 |
| Duration of HAART (years), median (range) * | 11.67±7.43 | 9 (1–27) | 11 (1–35) | 12 (1–38) | 0.14 |
| Viral load (copies/mL) | |||||
| Detectable Undetectable |
300 (39%) 470 (61%) |
30% | 38% | 34% | 0.18 |
| CD4 count (cells/mm3) | 555±272.1 | 460 (33–1573) |
540 (149–1923) |
503 (29–1670) |
0.10 |
Baseline characteristics were compared across HAART type groups using Kruskal-Wallis test. HAART type and duration was unknown for 170 included patients. NRTI: reverse transcriptase inhibitor NNRTI: Non-nucleoside reverse transcriptase IP: protease inhibitor.
* HAART duration was recorded in a subgroup of 600 patients.